Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. files reports and updates with the U.S. Securities and Exchange Commission (SEC) as a foreign private issuer with Class A ordinary shares listed on Nasdaq under APLM and public warrants under APLMW. These filings, which include Form 20-F annual reports and multiple Form 6-K current reports, provide detailed insight into the company’s clinical-stage oncology business, financial condition, capital structure and governance. On this page, you can review Apollomics’ SEC filings alongside AI-generated summaries that help explain key points in accessible language.
What Apollomics reports in its filings
Filings describe Apollomics as a clinical-stage biopharmaceutical or biotechnology company focused on oncology therapies, with a lead program in vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer and other tumors with MET alterations. The company’s reports outline its broader pipeline, including APL-122 and APL-102, and discuss program decisions such as the winding down of the uproleselan (APL-106) program after a Phase 3 bridging trial in China did not show favorable benefit.
Financial statements included in these filings detail research and development expenses, administrative expenses, impairment of intangible assets, net losses and equity or deficit positions over multiple periods. Liquidity discussions highlight Apollomics’ dependence on collaboration payments and financing transactions, including PIPE financings and upfront fees under its LaunXP agreement, and describe risks if expected payments are delayed or not received.
Governance, capital structure and warrants
Form 6-K reports document changes in the board of directors and executive management, the composition of board committees, and the appointment and resignation of directors. They also describe corporate actions such as the 1-for-100 reverse share split of Class A ordinary shares, adjustments to warrant terms and exercise prices, and Nasdaq listing compliance developments. For holders or analysts of APLMW warrants, these filings explain how the reverse split affected the number of shares issuable upon exercise and the revised exercise price.
Using AI summaries for faster review
Because SEC filings can be lengthy and technical, this page pairs Apollomics’ original documents with AI-powered summaries that highlight key disclosures, such as clinical program status, material agreements, PIPE subscription terms, liquidity risks and changes in control or governance. You can quickly identify items related to oncology trial outcomes, collaboration disputes, reverse share splits, and the company’s assessment of its ability to continue as a going concern, then drill down into the full text of 20-F, 6-K and related exhibits for deeper analysis.
Apollomics Inc. disclosed on a Schedule 13D that Hung-Wen (Howard) Chen and his wholly owned vehicle, King Regent Management Limited, together hold 896,362 Class A ordinary shares, representing 41.8% of the issuer's outstanding Class A shares (2,146,151 shares outstanding as disclosed). The holdings comprise 133,334 shares directly held by Mr. Chen and 763,028 shares held by King Regent. The filing amends a prior Schedule 13G and notes that Mr. Chen is Chairman and CEO; King Regent is a private investment holding company wholly owned by him. The transaction source is identified as PIPE subscription agreements executed on September 2, 2025, and the filing includes a joint filing agreement as an exhibit.
Apollomics Inc. Schedule 13G/A filed by Maxpro Investment Co., Ltd discloses that the reporting person beneficially owns 105,071 Class A ordinary shares, representing 4.90% of the Class A shares outstanding based on 2,146,151 shares. The total includes 101,248 currently outstanding Class A shares and 3,823 Class A shares issuable upon exercise of warrants exercisable within 60 days of this filing. The filing states that on September 3, 2025 the issuer completed a private placement of 1,042,803 Class A shares, after which Maxpro ceased to be a beneficial owner of more than 5% of the Class A shares; this amendment is an exit filing reflecting that change.
Apollomics Inc. reports major governance and leadership changes following a September 4, 2025 board meeting. The board appointed Yi-An Chu and Chen-Huan (Jack) Jan as new independent directors, bringing the board to seven members, five of whom are independent. The board also reconstituted key committees: the audit committee now includes Po-Jen Hsueh, Hsien-Shu Tsai (chairman), and Yi-An Chu; the compensation committee includes Moses Chen (chairman), Hsien-Shu Tsai, and Yi-An Chu; and the nominating and corporate governance committee includes Moses Chen, Po-Jen Hsueh, and Chen-Huan Jan (chairman).
The board named Hung-Wen (Howard) Chen as Chairman and Chief Executive Officer, appointed Yi-Kuei Chen as Chief Operating Officer, and Peter Lin as Chief Financial Officer, each bringing extensive experience in biotechnology, technology, finance, and private equity. The filing also corrects prior disclosure by stating that, following issuance of PIPE shares, Howard Chen and his affiliates beneficially own approximately 42% of Apollomics’ outstanding Class A ordinary shares, while Maxpro Investment Co., Ltd. and its affiliates beneficially own approximately 4.9%.
Apollomics Inc. filed a Form 6-K reporting biographical details for Po-Jen Hsueh and attaching an exhibit reference to a PIPE Subscription Agreement dated September 2, 2025. The filing states Mr. Hsueh has over 15 years of experience in operations, finance, and business development in the biopharmaceutical sector, including roles as COO of ACT Genomics and prior work at TaiGen Biotechnology where he participated in multiple financing rounds that together raised $114 million USD. The registrant also notes it will furnish omitted schedules and exhibits to the SEC upon request. The report is signed by Howard Chen, Chairman, dated September 3, 2025.
Apollomics Inc. reported that, due to its cash position, it is terminating all U.S. employees, including its Chief Executive Officer, Dr. Guo-Liang Yu, and Chief Financial Officer, Dr. Matthew Plunkett, effective August 29, 2025. This indicates a severe reduction of U.S. operations and leadership.
The company also stated that it expects to discontinue all activities related to its SPARTA clinical trial as soon as possible, signaling a shutdown of this development program. In addition, Apollomics has called an Extraordinary General Meeting of Shareholders for September 4, 2025, to seek shareholder approval for winding up the company, which would effectively bring its corporate existence to an end if approved.